These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 28632883

  • 1. Importance of immunogenicity testing for cost-effective management of psoriasis patients treated with adalimumab.
    Mota F, Neves E, Oliveira JC, Selores M, Torres T.
    Acta Dermatovenerol Alp Pannonica Adriat; 2017 Jun; 26(2):33-35. PubMed ID: 28632883
    [Abstract] [Full Text] [Related]

  • 2. Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis.
    Mostafa NM, Nader AM, Noertersheuser P, Okun M, Awni WM.
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):490-497. PubMed ID: 27545848
    [Abstract] [Full Text] [Related]

  • 3. Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence.
    Lombardi G, Perego S, Sansoni V, Diani M, Banfi G, Altomare G.
    BMJ Open; 2016 Dec 09; 6(12):e011941. PubMed ID: 27940624
    [Abstract] [Full Text] [Related]

  • 4. Determination of adalimumab and etanercept trough levels and drug antibodies in long-term psoriasis treatment: a single-centre cohort study.
    Manriquez J, Alsina-Gibert M.
    Clin Exp Dermatol; 2017 Jan 09; 42(1):14-20. PubMed ID: 27943384
    [Abstract] [Full Text] [Related]

  • 5. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up.
    Menting SP, van Lümig PP, de Vries AC, van den Reek JM, van der Kleij D, de Jong EM, Spuls PI, Lecluse LL.
    JAMA Dermatol; 2014 Feb 09; 150(2):130-6. PubMed ID: 24352354
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M, McBride D, Gilloteau I, O'Neill C, Neidhardt K, Graham CN.
    J Eur Acad Dermatol Venereol; 2018 Dec 09; 32(12):2191-2199. PubMed ID: 29729105
    [Abstract] [Full Text] [Related]

  • 7. The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.
    Chiu HY, Chu TW, Cheng YP, Tsai TF.
    PLoS One; 2015 Dec 09; 10(11):e0142930. PubMed ID: 26566272
    [Abstract] [Full Text] [Related]

  • 8. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study.
    Mahil SK, Arkir Z, Richards G, Lewis CM, Barker JN, Smith CH.
    Br J Dermatol; 2013 Aug 09; 169(2):306-13. PubMed ID: 23550925
    [Abstract] [Full Text] [Related]

  • 9. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
    Takahashi N, Noda S, Taniguchi T, Adachi M.
    Int J Dermatol; 2015 Oct 09; 54(10):1194-8. PubMed ID: 26016819
    [Abstract] [Full Text] [Related]

  • 10. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
    Talamonti M, Galluzzo M, Bernardini N, Caldarola G, Persechino S, Cantoresi F, Egan CG, Potenza C, Peris K, Bianchi L.
    J Eur Acad Dermatol Venereol; 2018 Oct 09; 32(10):1737-1744. PubMed ID: 29776016
    [Abstract] [Full Text] [Related]

  • 11. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing.
    Verstockt B, Moors G, Bian S, Van Stappen T, Van Assche G, Vermeire S, Gils A, Ferrante M.
    Aliment Pharmacol Ther; 2018 Oct 09; 48(7):731-739. PubMed ID: 30109889
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis.
    Carrascosa JM, Toro Montecinos M, Ballescá F, Teniente Serra A, Martínez Cáceres E, Ferrándiz C.
    J Dermatolog Treat; 2018 Mar 09; 29(2):140-144. PubMed ID: 28604127
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study.
    Ara-Martín M, Pinto PH, Pascual-Salcedo D.
    J Dermatolog Treat; 2017 Nov 09; 28(7):606-612. PubMed ID: 28274164
    [Abstract] [Full Text] [Related]

  • 16. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.
    Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Philipp S, Spelman L, Zhang N, Strober B.
    Br J Dermatol; 2017 Dec 09; 177(6):1562-1574. PubMed ID: 28755394
    [Abstract] [Full Text] [Related]

  • 17. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
    Gibellini L, De Biasi S, Bianchini E, Bartolomeo R, Fabiano A, Manfredini M, Ferrari F, Albertini G, Trenti T, Nasi M, Pinti M, Iannone A, Salvarani C, Cossarizza A, Pellacani G.
    PLoS One; 2016 Dec 09; 11(12):e0167757. PubMed ID: 27936119
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB.
    J Am Acad Dermatol; 2017 Mar 09; 76(3):418-431. PubMed ID: 28057361
    [Abstract] [Full Text] [Related]

  • 19. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M, Nakamura M, Zhu TH, Farahnik B, Koo J, Bhutani T.
    J Dermatolog Treat; 2017 Sep 09; 28(6):488-491. PubMed ID: 28042711
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.